Shanghai Sailybio Biomedical Co., Ltd. has deep expertise in immunology and cell technology, and is a "Specialized, Refined, Distinctive and Innovative" enterprise focused on providing R&D services for innovative drug development. The company's predecessor was Shanghai Saily Biotech Co., Ltd., founded in 2015, which later underwent a strategic integration with Shanghai Xuanfeng Biotech Co., Ltd. and was renamed accordingly—marking a further expansion of its business scope and a comprehensive upgrade of its integrated service capabilities.
Founded more than ten years ago, the company has consistently operated in compliance with regulations and maintained stable operations, building an integrated service system covering cell isolation services, in vitro efficacy evaluation, clinical project management, and the supply of testing products. The company has its own in-house R&D laboratory platform, has established a BSL-2 pathogenic microorganism laboratory, and has obtained GB/T 19001-2016/ISO 9001:2015 quality management system certification. Centered on technological innovation and grounded in compliant service delivery, the company—through its professional technical capabilities and reliable service quality—has served numerous leading domestic and international biopharmaceutical companies and research institutions, deeply empowering many innovative drug R&D pipelines. It has earned widespread trust from clients, helping them accelerate the development of innovative drugs and advance more new drugs from early-stage research into clinical application, ultimately improving patient health.
Creating Infinite Possibilities For Life Science application, and improving patient healt.
Accelerate innovative drug development advancing more new drugs from early-stage research to clinical.
Customer First, People-Oriented.
Completed a strategic upgrade and officially renamed to Shanghai Sailybio Biomedical Co., Ltd.
Obtained a Laboratory Animal License.
Certified by GB/T 19001-2016 / ISO 9001:2015.
Established a CRO service team to provide pre-clinical R&D services.
Obtained the Shanghai Pathogenic Microorganism Laboratory Filing Certificate; recognized as a Shanghai High-Tech Enterprise.
Shanghai Xuanfeng formed a clinical team to provide CRO, SMO, and other related services; joined the Chinese Society for Cell Biology (CSCB).
Developed standardized cell preparation services.
Shanghai Xuanfeng Biotech Co., Ltd. was established, forming the initial technical service team.
Shanghai Saily Biotechnology Co., Ltd. was founded.
Leveraging a mature isolation and sorting technology platform, Sailybio provides one-stop cell isolation services ranging from PBMC to finely characterized cell subsets. Our service catalog covers over 20 cell types from multiple sources, including human, non-human primate, and cord blood samples.
● Basic PBMC isolation services (premium PBMC, whole blood PBMC, cord blood CBMC, non-human primate PBMC, etc.) ● T/B/NK immune cell subset sorting ● Serum/plasma separation ● Fully compliant, traceable data workflows ● Rigorous quality control system and professional cold-chain logistics
Sailybio offers comprehensive in vitro efficacy evaluation services covering antibody therapeutics, cell therapy, and small-molecule drugs.
● In vitro efficacy assays (ADCC, ADCP, cell depletion, CRS assessment, etc.) ● Cell binding and functional assays (FACS binding, MLR, T-cell functional assays, etc.) ● Molecular-level testing (multiplex cytokine panels, apoptosis assays, serum stability testing, etc.) ● Cell induction/expansion platforms (T/NK/Treg activation and expansion, DC/macrophage induction and expansion) ● Customized experimental protocols available upon request
Sailybio provides biological sample collection services from healthy donors and patients with autoimmune diseases, including peripheral blood mononuclear cells, cord blood, cord tissue, mobilized stem cells, and tumor tissue samples, with customized collection protocols available.
● Streamlined operating procedures for efficient, professional project execution ● Supported over a dozen sponsors in obtaining ethics committee approval and human genetic resources (HGR) clearance for sample collection ● Extensive clinical and HGR expert networks and hospital resources ● Strong responsiveness in core regions ● End-to-end cold-chain delivery
Sailybio's detection product line supports a wide range of research and development needs.
● Anti-FMC63 and Anti-(G4S)n Linker detection antibodies, available across multiple fluorescence channels and specifications ● Anti-ADC Payload antibodies for highly specific monitoring of dynamic payload release from ADC drugs ● ELISA kits (double-antibody sandwich method), compatible with serum, plasma, tissue homogenate, cell supernatant, urine, and other sample types — high specificity, high sensitivity, minimal background interference ● Original imported South American (Uruguay-sourced) fetal bovine serum, low endotoxin (<10 EU/ml) ● Detailed COA reports and free trial support available
Long Press to Scan QR Code
Scan QR Code
